FST and prostate cancer: Follistatin, which bioneutralises activin A, was validated as a key factor required for fibroblasts to promote prostate cancer cell proliferation and migration in vitro, and for xenograft growth from co‐culture grafts, and therefore represents a potential therapeutic target.